Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension: A randomized, double-blind trial [2]

Cardiology

Volumn 99, Issue 3, 2003, Pages 169-170

  Martina, Benedict ^a   Dieterle, Thomas ^a   Sigle, Jörg Peter ^a   Surber, Christian ^a   Battegay, Edouard ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; LOSARTAN; TELMISARTAN;

ANALYTIC METHOD; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISEASE SEVERITY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE DETERMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0038646391     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070675     Document Type: Letter

References (10)

1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
2. Martina B, Dieterle T, Weinbacher M, Battegay E: Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled comparative study. Cardiology 1999;92:110-114.
3. Cuspidi C, Lonati L, Sampieri L, Valagussa L, Macca G, Leonetti G, Zanchetti A: Effects of losartan on blood pressure and left ventricular mass in essential hypertension. High Blood Pressure 1998;7:75-79.
4. Burnier M, Maillard M: The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001;10(suppl 1):S6-S11.
5. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D: Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998;20:205-221.
6. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-2042.
7. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-569.
8. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlof B: Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction study. J Hypertens 2002;20:1445-1450.
9. Mallion J, Siche J, Lacourcière Y: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-664.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001;345:861-869.